Global Drugs for Short Bowel Syndrome Market Strategic Research Report (2025–2036)
Western Market Research predicts that the Global Drugs for Short Bowel Syndrome Market was valued at USD 1,850.4 Million in 2025 and is expected to reach USD 4,120.8 Million by the year 2036, growing at a CAGR of 7.5% globally during the forecast period.
1. Global Drugs for Short Bowel Syndrome Market Overview
Short Bowel Syndrome (SBS) is a complex, rare malabsorptive condition resulting from the surgical removal of a large portion of the small intestine or its functional failure. The market for SBS therapeutics is a high-value niche within the orphan drug sector. Historically, treatment was limited to Parenteral Nutrition (PN); however, the advent of intestinal rehabilitation therapies—specifically GLP-2 analogs—has revolutionized the market by reducing PN dependency and improving the quality of life for chronic patients.
The research study involves a deep dive into biological innovation, orphan drug designations, and the transition from daily injections to long-acting formulations. This report calculates present and past market values to forecast potential market management through 2036, factoring in historical data from 2020–2024.
2. Impact of COVID-19 on Drugs for Short Bowel Syndrome Market
The COVID-19 pandemic significantly affected the SBS market in 2020 through two primary channels:
-
Logistical Challenges: SBS patients are highly dependent on specialized drugs and Parenteral Nutrition (PN) supplies. Supply chain disruptions initially caused anxiety regarding stockouts of essential biologics.
-
Care Transition: The pandemic accelerated the shift toward home-based care and telehealth. Hospitals prioritized reducing the time SBS patients spent in clinical settings to lower infection risks, leading to a surge in home-delivered specialized therapeutics.
Post-pandemic, the market has seen a sustained emphasis on self-administration and long-acting drugs that minimize the frequency of clinical visits.
3. Global Drugs for Short Bowel Syndrome Market Segmentation
By Drug Class:
-
GLP-2 (Glucagon-like Peptide-2) Analogs: The dominant segment (e.g., Teduglutide). These promote intestinal growth and increase absorption.
-
Growth Hormones: Utilized to enhance the adaptive response of the remaining bowel.
-
Glutamine: Often used in conjunction with growth hormones to support enterocyte health.
-
Anti-diarrheal & Anti-secretory Agents: Supportive therapies to manage fluid loss.
-
GLP-1/GLP-2 Dual Agonists (Emerging Segment): Next-generation therapies currently in clinical pipelines.
By Route of Administration (New Segment):
-
Injectable (Subcutaneous/Intravenous): The primary method for biologics.
-
Oral: Developing segment for supportive medications and small-molecule research.
By Patient Demographics (New Segment):
-
Adult: Largest revenue contributor due to a higher volume of surgical resections.
-
Pediatric: Highly specialized segment focusing on congenital conditions like gastroschisis.
By Distribution Channel:
-
Hospital Pharmacies: Primary source for initial therapy and acute cases.
-
Retail Pharmacies: Local access for maintenance therapy.
-
Online/Specialty Pharmacies: Rapidly growing due to the specialized handling and home-delivery requirements of biologics.
4. Top Key Players Covered
-
Takeda Pharmaceutical Company Limited (Market leader with Gattex/Revestive)
-
Zealand Pharma A/S
-
Merck KGaA
-
Ironwood Pharmaceuticals (Acquired VectivBio)
-
9 Meters Biopharma, Inc.
-
Emmaus Life Sciences, Inc.
-
Ardelyx, Inc.
-
Hanmi Pharmaceutical
-
Nutrinia Ltd.
-
OxThera AB
-
Naia Pharmaceuticals
-
GLyPharma Therapeutic
5. Regional Analysis
-
North America: Holds the largest market share (~45%) due to high orphan drug prices, advanced diagnostic capabilities, and robust reimbursement frameworks (particularly the U.S. and Canada).
-
Europe: Second-largest market, characterized by high awareness and standardized clinical guidelines in Germany, the UK, and France.
-
Asia-Pacific: Expected to witness the highest CAGR through 2036. Drivers include improving healthcare infrastructure in China and India and rising awareness of rare gastrointestinal diseases.
-
South America & MEA: Emerging markets where growth is linked to the adoption of international treatment standards in specialized metabolic centers.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants (Low): High R&D costs, stringent regulatory pathways for orphan drugs, and specialized manufacturing requirements act as formidable barriers.
-
Bargaining Power of Buyers (Medium-High): Large insurance payers and government health bodies exert pressure on the pricing of high-cost SBS biologics.
-
Bargaining Power of Suppliers (Low): Standard chemical and biological precursors are widely available, though proprietary cell lines for biologics are tightly controlled.
-
Threat of Substitutes (Low): There are no direct substitutes for intestinal rehabilitation drugs; the only alternative is long-term Parenteral Nutrition, which carries high complication risks.
-
Competitive Rivalry (Medium): While Takeda dominates, Zealand Pharma and Ironwood are introducing competitive long-acting formulations, intensifying rivalry.
7. SWOT Analysis
-
Strengths: High patient adherence; Orphan Drug status (market exclusivity and tax credits).
-
Weaknesses: Extremely high treatment costs; dependency on cold-chain logistics for biologics.
-
Opportunities: Expansion into pediatric indications; development of once-weekly formulations.
-
Threats: Payer-mandated price caps; potential for biosimilar entry in the long term.
8. Trend Analysis
-
Shift to Long-Acting Formulations: The transition from once-daily subcutaneous injections (Teduglutide) to once-weekly formulations (Apraglutide) is the defining trend of the decade.
-
Intestinal Rehabilitation Centers: Growth of specialized clinics that integrate dietary management with advanced drug therapy.
-
Digital Patient Monitoring: Use of mobile apps to track fluid intake and Parenteral Nutrition volume to optimize drug dosage.
9. Drivers & Challenges
-
Drivers:
-
Rising incidence of Crohn’s disease and vascular accidents leading to bowel resection.
-
Favorable government policies for rare disease drug development.
-
Technological breakthroughs in GLP-2 analog stability and efficacy.
-
-
Challenges:
-
Strict reimbursement criteria that require patients to fail PN-only therapy first.
-
High rate of misdiagnosis or delayed diagnosis in emerging economies.
-
10. Value Chain Analysis
-
R&D: Focus on peptide engineering and clinical trials for orphan status.
-
Manufacturing: Biologic production involving complex protein expression and purification.
-
Specialized Logistics: Stringent cold-chain management required for biologics.
-
Specialty Pharmacy Distribution: Direct-to-patient delivery of temperature-sensitive medications.
-
Patient Support Programs: Manufacturer-led programs to assist with insurance navigation and injection training.
11. Quick Recommendations for Stakeholders
-
For Manufacturers: Invest in Long-Acting GLP-2 Analogs to capture the market share of patients seeking a lower "treatment burden."
-
For Investors: Focus on companies with Pediatric Label Expansions, as this segment is underserved and offers extended exclusivity.
-
For Healthcare Providers: Implement integrated intestinal rehabilitation protocols to move patients from Parenteral Nutrition to pharmacological therapy more efficiently.
-
For Payers: Develop Value-Based Contracts where payment is tied to the measurable reduction in Parenteral Nutrition volume.
1. Market Overview of Drugs for Short Bowel Syndrome
1.1 Drugs for Short Bowel Syndrome Market Overview
1.1.1 Drugs for Short Bowel Syndrome Product Scope
1.1.2 Market Status and Outlook
1.2 Drugs for Short Bowel Syndrome Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Drugs for Short Bowel Syndrome Historic Market Size by Regions
1.4 Drugs for Short Bowel Syndrome Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Drugs for Short Bowel Syndrome Sales Market by Type
2.1 Global Drugs for Short Bowel Syndrome Historic Market Size by Type
2.2 Global Drugs for Short Bowel Syndrome Forecasted Market Size by Type
2.3 GLP-2
2.4 Growth Hormone
2.5 Glutamine
2.6 Others
3. Covid-19 Impact Drugs for Short Bowel Syndrome Sales Market by Application
3.1 Global Drugs for Short Bowel Syndrome Historic Market Size by Application
3.2 Global Drugs for Short Bowel Syndrome Forecasted Market Size by Application
3.3 Hospital Pharmacies
3.4 Retail Pharmacies
3.5 Online Pharmacies
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Drugs for Short Bowel Syndrome Production Capacity Market Share by Manufacturers
4.2 Global Drugs for Short Bowel Syndrome Revenue Market Share by Manufacturers
4.3 Global Drugs for Short Bowel Syndrome Average Price by Manufacturers
5. Company Profiles and Key Figures in Drugs for Short Bowel Syndrome Business
5.1 Ardelyx
5.1.1 Ardelyx Company Profile
5.1.2 Ardelyx Drugs for Short Bowel Syndrome Product Specification
5.1.3 Ardelyx Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.2 Emmaus Life Sciences
5.2.1 Emmaus Life Sciences Company Profile
5.2.2 Emmaus Life Sciences Drugs for Short Bowel Syndrome Product Specification
5.2.3 Emmaus Life Sciences Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.3 GLyPharma Therapeutic
5.3.1 GLyPharma Therapeutic Company Profile
5.3.2 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Product Specification
5.3.3 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.4 Merck
5.4.1 Merck Company Profile
5.4.2 Merck Drugs for Short Bowel Syndrome Product Specification
5.4.3 Merck Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.5 Naia Pharmaceuticals
5.5.1 Naia Pharmaceuticals Company Profile
5.5.2 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Product Specification
5.5.3 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.6 Nutrinia
5.6.1 Nutrinia Company Profile
5.6.2 Nutrinia Drugs for Short Bowel Syndrome Product Specification
5.6.3 Nutrinia Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.7 OxThera
5.7.1 OxThera Company Profile
5.7.2 OxThera Drugs for Short Bowel Syndrome Product Specification
5.7.3 OxThera Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.8 Sancilio & Company
5.8.1 Sancilio & Company Company Profile
5.8.2 Sancilio & Company Drugs for Short Bowel Syndrome Product Specification
5.8.3 Sancilio & Company Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.9 Takeda
5.9.1 Takeda Company Profile
5.9.2 Takeda Drugs for Short Bowel Syndrome Product Specification
5.9.3 Takeda Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
5.10 Zealand Pharma
5.10.1 Zealand Pharma Company Profile
5.10.2 Zealand Pharma Drugs for Short Bowel Syndrome Product Specification
5.10.3 Zealand Pharma Drugs for Short Bowel Syndrome Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Drugs for Short Bowel Syndrome Market Size
6.2 North America Drugs for Short Bowel Syndrome Key Players in North America
6.3 North America Drugs for Short Bowel Syndrome Market Size by Type
6.4 North America Drugs for Short Bowel Syndrome Market Size by Application
7. East Asia
7.1 East Asia Drugs for Short Bowel Syndrome Market Size
7.2 East Asia Drugs for Short Bowel Syndrome Key Players in North America
7.3 East Asia Drugs for Short Bowel Syndrome Market Size by Type
7.4 East Asia Drugs for Short Bowel Syndrome Market Size by Application
8. Europe
8.1 Europe Drugs for Short Bowel Syndrome Market Size
8.2 Europe Drugs for Short Bowel Syndrome Key Players in North America
8.3 Europe Drugs for Short Bowel Syndrome Market Size by Type
8.4 Europe Drugs for Short Bowel Syndrome Market Size by Application
9. South Asia
9.1 South Asia Drugs for Short Bowel Syndrome Market Size
9.2 South Asia Drugs for Short Bowel Syndrome Key Players in North America
9.3 South Asia Drugs for Short Bowel Syndrome Market Size by Type
9.4 South Asia Drugs for Short Bowel Syndrome Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Drugs for Short Bowel Syndrome Market Size
10.2 Southeast Asia Drugs for Short Bowel Syndrome Key Players in North America
10.3 Southeast Asia Drugs for Short Bowel Syndrome Market Size by Type
10.4 Southeast Asia Drugs for Short Bowel Syndrome Market Size by Application
11. Middle East
11.1 Middle East Drugs for Short Bowel Syndrome Market Size
11.2 Middle East Drugs for Short Bowel Syndrome Key Players in North America
11.3 Middle East Drugs for Short Bowel Syndrome Market Size by Type
11.4 Middle East Drugs for Short Bowel Syndrome Market Size by Application
12. Africa
12.1 Africa Drugs for Short Bowel Syndrome Market Size
12.2 Africa Drugs for Short Bowel Syndrome Key Players in North America
12.3 Africa Drugs for Short Bowel Syndrome Market Size by Type
12.4 Africa Drugs for Short Bowel Syndrome Market Size by Application
13. Oceania
13.1 Oceania Drugs for Short Bowel Syndrome Market Size
13.2 Oceania Drugs for Short Bowel Syndrome Key Players in North America
13.3 Oceania Drugs for Short Bowel Syndrome Market Size by Type
13.4 Oceania Drugs for Short Bowel Syndrome Market Size by Application
14. South America
14.1 South America Drugs for Short Bowel Syndrome Market Size
14.2 South America Drugs for Short Bowel Syndrome Key Players in North America
14.3 South America Drugs for Short Bowel Syndrome Market Size by Type
14.4 South America Drugs for Short Bowel Syndrome Market Size by Application
15. Rest of the World
15.1 Rest of the World Drugs for Short Bowel Syndrome Market Size
15.2 Rest of the World Drugs for Short Bowel Syndrome Key Players in North America
15.3 Rest of the World Drugs for Short Bowel Syndrome Market Size by Type
15.4 Rest of the World Drugs for Short Bowel Syndrome Market Size by Application
16 Drugs for Short Bowel Syndrome Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Global Drugs for Short Bowel Syndrome Market Segmentation
By Drug Class:
-
GLP-2 (Glucagon-like Peptide-2) Analogs: The dominant segment (e.g., Teduglutide). These promote intestinal growth and increase absorption.
-
Growth Hormones: Utilized to enhance the adaptive response of the remaining bowel.
-
Glutamine: Often used in conjunction with growth hormones to support enterocyte health.
-
Anti-diarrheal & Anti-secretory Agents: Supportive therapies to manage fluid loss.
-
GLP-1/GLP-2 Dual Agonists (Emerging Segment): Next-generation therapies currently in clinical pipelines.
By Route of Administration (New Segment):
-
Injectable (Subcutaneous/Intravenous): The primary method for biologics.
-
Oral: Developing segment for supportive medications and small-molecule research.
By Patient Demographics (New Segment):
-
Adult: Largest revenue contributor due to a higher volume of surgical resections.
-
Pediatric: Highly specialized segment focusing on congenital conditions like gastroschisis.
By Distribution Channel:
-
Hospital Pharmacies: Primary source for initial therapy and acute cases.
-
Retail Pharmacies: Local access for maintenance therapy.
-
Online/Specialty Pharmacies: Rapidly growing due to the specialized handling and home-delivery requirements of biologics.
4. Top Key Players Covered
-
Takeda Pharmaceutical Company Limited (Market leader with Gattex/Revestive)
-
Zealand Pharma A/S
-
Merck KGaA
-
Ironwood Pharmaceuticals (Acquired VectivBio)
-
9 Meters Biopharma, Inc.
-
Emmaus Life Sciences, Inc.
-
Ardelyx, Inc.
-
Hanmi Pharmaceutical
-
Nutrinia Ltd.
-
OxThera AB
-
Naia Pharmaceuticals
